There is no evidence for protection by SPf66 vaccines against P. falciparum in Africa. There is a modest reduction in attacks of P. falciparum malaria following vaccination with SPf66 in South America. There is no justification for further trials of SPf66 in its current formulation. Further research with SPf66 vaccines in South America or with new formulations of SPf66 may be justified.
P L A I N L A N G U A G E S U M M A R Y
The SPf66 vaccine has little or no effect on preventing malaria
The SPf66 vaccine was one of the first malaria vaccines to be tested extensively in endemic areas. SPf66 is a synthetic peptide vaccine containing antigens from the blood stages of malaria linked together with an antigen from the sporozoite stage. SPf66 has had 10 trials in Africa, Asia, and South America. Results were initially promising, but further trials showed only a small effect in some trials, and no effect in Africa. There is no evidence that SPf66 is effective enough to be introduced on a routine basis for prevention of malaria.
B A C K G R O U N D
Malaria is caused by four species of the parasitic protozoan Plasmodium, which are transmitted by many species of anopheline mosquitoes. Plasmodium falciparum is the most widespread and also the most serious form. Recent estimates of the annual number of clinical malaria cases worldwide range from 214 to 397 million (WHO 2002; Breman 2004) , although a higher estimate of 515 million (range 300 to 660 million) clinical cases of P. falciparum in 2002 has been proposed (Snow 2005) . Estimates of annual mortality (nearly all from P. falciparum malaria) are thought to be around 1.1 million (WHO 2002; Breman 2004) . Malaria deaths are believed to account for 3% of the world's total Disability Adjusted Life Years (DALYs) lost and 10% of DALYs in Africa (Breman 2004) . Malaria also significantly increases the risk of childhood death from other causes (Snow 2004) . Almost half of the world's population is exposed to the risk of malaria where they live (Hay 2004) , as are the increasing numbers of visitors to malarious areas.
Despite continued efforts to control malaria it remains a major health problem in many regions of the world, and new ways to prevent the disease are urgently needed. Early optimism for vaccines was tempered as the problems caused by genetic (hence, antigenic) variability of the parasite and the difficulty of generating high levels of durable immunity emerged. Recently, hope has been renewed by the development of several new vaccine candidates and delivery systems, as well as new formulations and adjuvants for previously existing candidates (Richie 2002; Ballou 2004) . Vaccines currently under evaluation include recombinant proteins, synthetic peptides (including multiple antigen peptides), DNA vaccines, inactivated whole parasites, and vaccines comprising mixtures of a large variety of potential antigens.
To be effective, a malaria vaccine could either prevent infection altogether or mitigate against severe disease and death in those who become infected despite vaccination. Four stages of the malaria parasite's life cycle (Figure 1 ) have been the targets of vaccine development efforts. The first two stages are often grouped as 'preerythrocytic stages' (ie before the parasite invades the human red blood cells): these are the sporozoites inoculated by the mosquito into the human bloodstream, and the parasites developing inside human liver cells. The other two targets are the stage when the parasite is invading or growing in the red blood cells (blood, merozoite, or erythrocytic stage); and the gametocyte stage, when the parasites emerge from red blood cells and fuse to form a zygote inside the mosquito vector (gametocyte, gamete or sexual stage). Vaccines based on the pre-erythrocytic stages usually aim to completely prevent infection, while blood stage vaccines aim to reduce (and preferably eliminate) the parasite load once a person has been infected. Gametocyte vaccines would prevent the parasite being transmitted to others through mosquitoes. An ideal vaccine would be effective against all parasite stages (Richie 2002). Given the complexity and wide range of malaria vaccines under development, we have chosen to consider them in three categories: (1) the SPf66 vaccine; (2) pre-erythrocytic vaccines (Graves 2006a); and the (3) blood-stage vaccines (Graves 2006b). This review considers trials of SPf66 vaccine, while other types of malaria vaccine are covered in separate forthcoming reviews; reviews of multi-stage and transmission-blocking vaccines will also be prepared when they have reached the trial stage. The SPf66 vaccine was first formulated and tested in Colombia ( Patarroyo 1988) and later also manufactured in the USA. SPf66 is a synthetic hybrid peptide polymer containing amino acid sequences derived from three P. falciparum asexual blood stage proteins (83, 55, and 35 kilodaltons) linked by repeat sequences from a protein found on the P. falciparum sporozoite surface (circumsporozoite protein). Therefore it is technically a multistage vaccine. SPf66 was one of the first types of vaccine to be tested in randomized controlled trials in endemic areas and is the vaccine that has undergone the most extensive field testing to date.
We have systematically reviewed the trials conducted to estimate the efficacy of SPf66 vaccine. Trials of SPf66 have been subgrouped by area of the world because the transmission rate of malaria is generally more intense in Africa than in South America and Asia. In this way we explore possible variation in efficacy dependent on the level of exposure of the host to infective mosquito bites, the age of the participants, and the seasonality of transmission, all of which contribute to the immune status of people living in the areas, which, in turn, can affect the response to a vaccine.
O B J E C T I V E S
To assess the effect of SPf66 malaria vaccines against P. falciparum, P. vivax, P. malariae, and P. ovale in preventing infection, disease, and death.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
People of any age who are challenged by a malaria infection. The challenge infection could be either a natural malaria infection (ie residents of malaria endemic areas) or a laboratory-induced infection (either from infected blood or bites of infected mosquitoes).
Types of interventions Intervention
• SPf66 vaccine.
Control
• Placebo or routine antimalarial control measures.
Types of outcome measures

Primary
• New malaria infection.
• Clinical malaria episodes.
• Fever episodes.
Secondary
• Death.
• Severe malaria.
• Admission to hospital.
• Admission to hospital with diagnosis of malaria.
• Parasite density.
• Prevalence of malaria.
• Anaemia.
Adverse events
• Local and systemic.
Search methods for identification of studies
We have attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press , and in progress).
Databases
We searched the following databases using the search terms and strategy described in 
Researchers and organizations
In preparing earlier versions of this review (Graves 2003) we contacted the following researchers working in the field: M Patarroyo, M Urdaneta, B Greenwood, and P Alonso. 
Reference lists
We checked the reference lists of all studies identified by the above methods.
Data collection and analysis
Selection of studies
Two people independently applied the inclusion criteria to all identified trials (Patricia Graves and an Editor of the Cochrane Infectious Diseases Group, or both authors). Differences were discussed until consensus was reached.
Data extraction and management
Each author independently extracted all data for analyses. Differences were resolved by discussion.
Assessment of risk of bias in included studies
Each author independently assessed the trials for four dimensions of quality: (1) method of generation of allocation sequence and (2) allocation concealment (both as adequate, inadequate, not done, or unclear according to Juni 2001); (3) blinding (double, ie investigators and participants were blinded; single, ie only participants blinded; neither blinded; or unclear), and (4) loss to follow up (proportion of those randomized who completed all doses and who completed follow up, if stated). Differences were resolved by discussion.
Data synthesis
We analysed the data using Review Manager 4.2. A fixed-effect model was used. Heterogeneity between trials in the outcomes was dealt with by subgrouping trials into geographical areas of the world. Results for dichotomous data are expressed as risk ratios (RR) of an outcome occurring in the vaccine group compared to the placebo group. The risk ratio may be converted to an estimate of vaccine efficacy by the following formula: Efficacy = (1-RR) x 100% Similarly, the 95% confidence interval (CI) for the vaccine efficacy may be obtained by substituting the upper and lower 95% CIs of the RR into the formula. This review includes outcomes only for those participants who received the full course of vaccine (usually three doses), if this was stated in the trials. Some trials did not report this information. Some trials included adjusted incidence rates, such as by village or the distance from a health facility, or performed survival analysis. This meta-analysis uses only unadjusted incidence rates based on the number of participants in each arm of the trial.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. See the 'Characteristics of included studies' for more detailed information.
Ten trials involving 9698 participants aged from one month to 86 years met the inclusion criteria. These trials were done during the years 1990 to 1998. Four of the SPf66 vaccine trials were conducted in South America (Valero 1993; Sempertegui 1994; Valero 1996 ; Urdaneta 1998), five in Africa (Alonso 1994; D'Alessandro 1995; Leach 1995; Masinde 1998; Acosta 1999) , and one in Asia (Nosten 1996) . All the included SPf66 trials were conducted in situations of natural challenge. The decision about which age group to include in a vaccine trial is based partly on epidemiological considerations and partly on safety concerns. Different areas vary greatly in endemicity, and this has consequences for the age-specific incidence of infection, and of severe disease and death. Repeated malarial infections and inoculations of sporozoites from mosquitoes (even if not causing clinical disease) gradually result in the development of what is referred to as 'partial' immunity, and as a result, fewer full-blown infections become likely. When an infection does become established, the numbers of parasites are generally lower than they are in people with no experience of infection, hence no immunity. Because clinical manifestations are related to the parasite density, clinical manifestations are generally less serious (or absent) in people with partial immunity than in immune 'naïve' individuals. In most of subSaharan Africa, malaria infection begins early in life. Very young children, who have yet to develop any immunity to malaria, suffer the most infections and the most severe consequences of infection. However in Brazil, Colombia, Ecuador, and Thailand, there are non-immune people (and therefore, symptomatic infections) among all age groups. As a result, most African trials have involved young children while other trials have included older children, all ages, or adults only. The exception in Africa was Masinde 1998, which was conducted with adults.
Vaccine source
Of the 10 trials, seven used vaccine prepared in Colombia ( Valero 1993; Alonso 1994; Sempertegui 1994; D'Alessandro 1995; Valero 1996; Urdaneta 1998; Acosta 1999) , one used vaccine manufactured in the USA (Nosten 1996) , one compared vaccine from both sources (Leach 1995), and one did not state the source (Masinde 1998). In all preparations, the peptide vaccine was adsorbed to alum, which served as an adjuvant. The placebos were tetanus toxoid vaccine in five of the trials (Valero 1993; Alonso 1994; Sempertegui 1994; Valero 1996 ; Urdaneta 1998), injected polio vaccine in two trials (D'Alessandro 1995; Leach 1995), hepatitis B vaccine in two trials (Nosten 1996; Masinde 1998) , and alum alone in one trial (Acosta 1999).
Participants
Three of the SPf66 trials were carried out in all age groups (Valero 1993; Sempertegui 1994; Valero 1996) , and one was with adults only (Masinde 1998). The Urdaneta 1998 trial included people aged seven to 60 years. The Nosten 1996 trial included children aged two to 15 years. Four trials were in children in areas of high endemicity: age at first dose was one to five years in Alonso 1994; six to 11 months in Leach 1995 and D'Alessandro 1995; and one month in Acosta 1999.
Dose
All but one trial used doses of 0.5 to 2 mg of SPf66 vaccine given at day zero, and one and six months; the Masinde 1998 trial gave doses at day zero, four months, and seven to eight months, but the doses are not stated. In all trials except one, experimental and placebo vaccines were given at visits specifically for that purpose. In Acosta 1999, the trial was designed to coincide with the Expanded Program on Immunization (EPI) vaccine schedule, so the first two doses of vaccine or placebo were given at the same time as the first and second diphtheria, tetanus, and acellular pertussis (DTP) vaccine (injected into the opposite thigh); oral polio vaccine was also given at both visits. The third dose was given at a specialized visit except for 39 children (3%), who received dose three concurrently with measles vaccine.
Definition of a clinical malaria case
Because of the differing levels of endemicity, trials used different definitions of a clinical malaria case. In the Alonso 1994 trial and both trials in The Gambia (D'Alessandro 1995; Leach 1995), the trials used fever together with a defined level of malaria parasites as a case definition, after having determined a cut-off level using the percentage of fevers which were likely attributable to malaria. In the Acosta 1999 trial, the primary outcome was the incidence of fever with any level of parasitaemia, although secondary analyses requiring at least certain levels of parasitaemia to define a case were also performed. In other endemic areas, the presence of parasitaemia alone, parasitaemia with fever, or parasitaemia with clinical symptoms defined a case. Case definitions are noted under 'Outcomes' in the 'Characteristics of included studies'.
Use of antimalarial drugs
In three of the five African trials of SPf66, parasites were cleared from all participants by chemotherapy before or shortly after vaccination (before each dose in the Alonso 1994 trial, before the first and third doses in the D'Alessandro 1995 trial, and one week after the second and third doses in the Masinde 1998 trial). This was done because of the high prevalence of parasitaemia in the target population and the difficulty this created for determining the incidence of new infections. In the Nosten 1996 trial in Thailand, children found to be parasitaemic at surveys conducted before vaccination or on the day of vaccination were treated.
Detecting malaria cases
Some trials detected malaria cases when participants reported for treatment (passive case detection), some conducted populationbased surveys at regular intervals (active case detection), and most used a combination of the two. The Nosten 1996 trial conducted the most intensive active surveillance (daily home visitation for 15 months) combined with cross-sectional surveys and detection of self-reported cases. In this review, for outcomes that include clinical malaria episodes (cases), both self-reported cases and results of population-based surveys have been combined, where possible.
Incidence and prevalence of malaria
All trials reported on the incidence or prevalence of P. falciparum malaria after vaccination. Incidence of P. vivax was also reported in all five trials conducted outside Africa. P. malariae is present at a low level in the African sites of trials, but incidence of this species after vaccination was not reported.
Length of follow up
Total length of follow up in the SPf66 trials ranged from eight months to two years. The two Gambian trials continued follow up into the second year after vaccination, although intensive surveillance was only conducted during 18 weeks of the malaria season in the second year of each trial (D'Alessandro 1995; Leach 1995) . In this review, the results of the first and second malaria seasons are reported separately.
Outcomes
The outcomes that we were able to extract from the trials were as follows: new malaria episode (P. falciparum) − by year of follow up in two trials; new malaria episode (P. vivax); death; admission to hospital; admission to hospital with diagnosis of malaria; prevalence of malaria; and adverse events. Definitions of a new malaria episode varied by trial and are given in the 'Characteristics of included studies'.
Risk of bias in included studies
Generation of allocation sequence
The randomization method was described explicitly in four trials, in which it was regarded as adequate (Nosten 1996; Valero 1996; Urdaneta 1998; Acosta 1999). The rest were unclear.
Allocation concealment
Seven trials described adequate methods of allocation concealment, using central randomization and vials or syringes that were identical, masked, or placed in coded envelopes. In three trials allocation concealment was not done or unclear (Leach 1995; Masinde 1998; Urdaneta 1998).
Blinding
All trials were stated to be double blind with the exception of Masinde 1998, which was stated to be blinded but did not specify double blind.
Loss to follow up
The proportion of participants lost to follow up was high in five of the 10 SPf66 trials (Valero 1993; Sempertegui 1994; Valero 1996; Masinde 1998; Urdaneta 1998) . In three of the South American trials, more than 20% of participants receiving the first vaccine dose withdrew before completion of the vaccine schedule (Valero 1993; Valero 1996; Urdaneta 1998) . In Valero 1993, of those failing to complete the doses, one third were excluded because of "fever, allergy, pregnancy or malaria treatment" although the number due to each cause and breakdown by group is not provided. The rest were excluded because of absence, migration, or refusal. The high level of post-randomization exclusions led to an imbalance in numbers between vaccine and placebo groups in this trial and is a potential source of bias. This potential bias seemed to be less of a problem in Urdaneta 1998 since the losses were of similar proportion in the two trial arms, and analysis showed that the losses were independent of malaria parasitaemia or adverse reactions to vaccine. The Masinde 1998 trial had initially 85 participants randomized and more than 20% of participants dropped out of the trial postrandomization (balanced between trial arms), but apparently none left the trial after the first dose. In the D'Alessandro 1995 trial, although the dropout rate was small, a mistake in coding syringes necessitated exclusion of a large number of the placebo group who wrongly received vaccine, leading to an imbalance in numbers between groups. In both Leach 1995 and D'Alessandro 1995, the dropout rate in the first year was very low, but greater than 10% of the participants could not be traced for follow up in the second year.
Effects of interventions 1. New malaria episode (P. falciparum)
Nine trials used new episodes of P. falciparum malaria as their primary outcome and reported data on the incidence of the first or only attack of clinical malaria. One trial reported prevalence as the major outcome (Masinde 1998). Considering the trials individually, two trials showed significant protective effect against a new malaria infection (Valero 1993; Valero 1996) and the rest did not (Analysis 1.1). The combined RR from all nine trials was 0.90 (95% CI 0.84 to 0.96), giving an estimated vaccine efficacy of 10% (95% CI 4% to 16%). However, there was large heterogeneity between trials (chi-squared 29.10, df 8, I 2 72.5%), indicating that a combined estimate may not be a fair representation of the 'typical' effect of the vaccine. The endemicity of malaria is greater in Africa than in the other sites of trials, and all the trials in Africa that used incidence as an outcome were performed in young children. To investigate whether the observed heterogeneity was related to endemicity levels, we subgrouped trials into those taking place in Africa, South America, or Asia (Analysis 1.1). In African trials, the combined RR was 0.98 (95% CI 0.90 to 1.07), showing no evidence of efficacy. In South American trials, the combined RR was 0.72 (95% CI 0.63 to 0.82), suggesting that in this area of the world the vaccine was significantly protective against P. falciparum with an efficacy of 28% (95% CI 18% to 37%). There was no evidence for efficacy in one trial from Asia (Nosten 1996) . Two trials in The Gambia followed children during the second malaria season after vaccination, but there was no evidence of efficacy in the second year (Analysis 1.2).
New malaria episode (P. vivax)
Five trials reported new malaria infections with P. vivax. As for P. falciparum, these trials were subgrouped according to area of the world. In South American trials, there was a suggestion that the vaccine increased the incidence of P. vivax infections (Analysis 1.3). The combined RR for the four trials in South America was 1.16 (95% CI 1.01 to 1.32). The one trial in Asia showed the opposite trend (RR 0.90, 95% CI 0.83 to 0.98).
Serious outcomes: death, admission to hospital, and admission to hospital with a diagnosis of malaria
These serious outcomes were reported only in some of the African trials (Analysis 1.4, Analysis 1.5, and Analysis 1.6). Total deaths and admissions are included in these trials because the cause of death or admission to hospital may not have been correctly ascribed, and also because malaria may have been a secondary factor in deaths from other causes. The SPf66 vaccine had no statistically significant effect on these serious outcomes in the few trials that reported them (Alonso 1994; D'Alessandro 1995; Acosta 1999).
Prevalence
One trial reported prevalence as the major outcome (Masinde 1998). There was no evidence for reduction in prevalence of P. falciparum in adults by the vaccine in this trial (Analysis 1.7).
Systemic and local adverse events
The frequency of local and systemic adverse events after vaccination with SPf66 was recorded after time periods varying from one hour to two weeks. The results are reported in Figure 2 In the overall trial groups given non-intensive surveillance for adverse events, there were a total of three severe systemic adverse events in the vaccine group (two hypotension, one facial oedema) and two in the placebo (alum) group (one hypotension, one rash). There was also a higher proportion of allergic reactions in the vaccinated group, particularly in the Nosten 1996 trial where a large number of SPf66 recipients reported bilateral cutaneous reactions at the second or third dose, suggesting sensitization by the vaccine. This reaction had been observed previously in phase one non-randomized trials of SPf66 (Gordon 1996; Migasena 1997; Nosten 1997), which are not included in this review. These bilateral cutaneous reactions resolved within 24 hours with symptomatic treatment. Three cases of contralateral induration were also observed in the Alonso 1994 trial at the second or third dose, but two of these were in the placebo group (tetanus toxoid plus alum). In the Acosta 1999 trial, bilateral cutaneous reactions were also observed after the first dose of vaccine or placebo (which was alum), presumably at the site of DTP vaccination that was given in the other thigh. Frequencies of these reactions were no different between vaccine and placebo groups. Intense surveillance of the initial vaccinated group in the Acosta 1999 trial (48 children given vaccine and 50 given placebo) resulted in high frequencies of reported systemic adverse events, but the proportions were higher in the placebo than the vaccine group after each dose. The proportion of children with fever after vaccination was higher in the Nosten 1996 trial (11% to 16%) than in most of the other trials, although 10% to 13% of the placebo group also reported fevers after vaccination with the Engerix-B hepatitis vaccine in this trial.
D I S C U S S I O N
SPf66 malaria vaccine was not efficacious in five good quality trials in Africa. Four of these trials (which assessed incidence of new P. falciparum episodes) were in young children. The one trial in African adults assessed prevalence. In South America, four trials suggested that the vaccine has a low but statistically significant efficacy of 28% (95% CI 18% to 37%) against new episodes of P. falciparum. However, all four South American trials suffered from a high frequency of dropouts and losses to follow up. The four trials in South America also suggested a slightly elevated incidence of P. vivax in the vaccine groups, possibly demonstrating competition between the two malaria species. No effect of the vaccine was apparent in Asia against either malaria species, but this was studied in only one trial.
No significant effect of the vaccine on serious outcomes of malaria such as death or admission to hospital was apparent. However the trials were not designed to have sufficient power to evaluate vaccine efficacy against these rarer events. Although some allergic and bilateral cutaneous reactions were reported, the frequency of serious adverse events after immunization with SPf66 was not significantly higher than for the 'placebo' vaccines (mainly hepatitis B and tetanus toxoid for the first doses, and adjuvants alone for the second and third).
The SPf66 malaria vaccine did not work as well as had been hoped. In the 1990s, much attention focused on this vaccine, and there was controversy about its effectiveness. It is apparent from this review that SPf66 is not effective enough for routine use, and attention has moved on to other vaccine types which are described in separate reviews. It is possible that re-formulations of SPf66 to improve its effectiveness may lead to further trials of this vaccine outside Africa. For example, the adjuvant QS21 is being tested in an attempt to improve the immunogenicity of SPf66 (Kashala 2002).
The trials described here used a wide range of different definitions of a malaria case, and different methods and frequencies of surveillance. Close attention should be paid to these issues in trial design, and their potential effects on estimation of vaccine efficacy. In deciding on a case definition, there is a trade-off between the high sensitivity required for statistical power and the high specificity required to determine vaccine efficacy. Intensive population-based surveillance for case detection could lead to inclusion of more mild and possibly self-limiting cases of malaria. This might underestimate the effect of the vaccine compared to trials that relied more heavily on self-referral for treatment. It appears unlikely, however, that these factors are responsible for the lack of demonstrated efficacy of the SPf66 vaccine in Africa. Most trials in Africa used a case definition based on clinical symptoms as well as demonstration of parasitaemia, and used a mixture of active and passive surveillance.
A U T H O R S ' C O N C L U S I O N S Implications for practice
There is no evidence to support the introduction of SPf66 vaccine for routine use in prevention of malaria, either in Africa or in other regions of the world.
Implications for research
There is no justification for further trials of SPf66 in its current formulation for protection against malaria in Africa. The modest efficacy observed against P. falciparum in South America suggests that further research on new formulations of SPf66 with increased immunogenicity may be justified in areas outside Africa.
A C K N O W L E D G E M E N T S
The authors are grateful to Tom Smith and Malcolm Molyneux for their comments and to Manuel Patarroyo, Margarita Urdaneta, 
